Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: John Metcalf who wrote (5095)	11/18/1997 2:11:00 AM
From: scaram(o)uche	Respond to of 9262

[ biobio ] Following on John's comments....... ARIA is as good as they get, from a science perspective. Lots of cash flowing through the labs, while the burn is low. From a product development stand, they're not exactly "charts for quick cash" material, however. That is, they have zip in clinical trials. I own them, and they fit well in a "throw them in the closet and take a look in 5 years" portfolio. Do I hear the big sto Gods groaning? :-) CELG...... I don't think much of thalidomide for the indications where CELG is in the lead. Their second-generation variants are strong supressants of an inflammatory molecule, a particularly pesky creature called TNF. I owned them, a couple of years ago, for a sudden upward run, but I don't own them now. KDUS..... a screening company focused on "G proteins" and expression in yeast. Good stuff, but early stage and slightly clouded by a patent dispute with Sibia Neuro. CEO, Levin, was full of bluster at last year's H&Q. 'Tis the season.......